7ZW3

Crystal Structure of human MAO B in complex with (Z)-N-benzyl-1-(8-hydroxyquinolin-2-yl)methanimine oxide (inhibitor 19)

This is a non-PDB format compatible entry.

Summary for 7ZW3

• Entry DOI: 10.2210/pdb7zw3/pdb
• Descriptor: Amine oxidase [flavin-containing] B, FLAVIN-ADENINE DINUCLEOTIDE, N-DODECYL-N,N-DIMETHYL-3-AMMONIO-1-PROPANESULFONATE, ... (5 entities in total)
• Functional Keywords: monoamine oxidase, alzheimer's disease, enzyme, drug, mitochondrial membrane, flavoprotein
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 2
• Total formula weight: 120476.28

Authors

Binda, C.,Gottinger, A. (deposition date: 2022-05-18, release date: 2023-03-29, Last modification date: 2024-10-23)

Primary citation

Knez, D.,Diez-Iriepa, D.,Chioua, M.,Gottinger, A.,Denic, M.,Chantegreil, F.,Nachon, F.,Brazzolotto, X.,Skrzypczak-Wiercioch, A.,Meden, A.,Pislar, A.,Kos, J.,Zakelj, S.,Stojan, J.,Salat, K.,Serrano, J.,Fernandez, A.P.,Sanchez-Garcia, A.,Martinez-Murillo, R.,Binda, C.,Lopez-Munoz, F.,Gobec, S.,Marco-Contelles, J.
8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases.
Acta Pharm Sin B, 13:2152-2175, 2023

PubMed Abstract: We describe the development of quinolylnitrones (QNs) as multifunctional ligands inhibiting cholinesterases (ChEs: acetylcholinesterase and butyrylcholinesterase-hBChE) and monoamine oxidases (hMAO-A/B) for the therapy of neurodegenerative diseases. We identified QN , a simple, low molecular weight nitrone, that is readily synthesized from commercially available 8-hydroxyquinoline-2-carbaldehyde. Quinolylnitrone has no typical pharmacophoric element to suggest ChE or MAO inhibition, yet unexpectedly showed potent inhibition of hBChE (IC = 1.06 ± 0.31 nmol/L) and hMAO-B (IC = 4.46 ± 0.18 μmol/L). The crystal structures of with hBChE and hMAO-B provided the structural basis for potent binding, which was further studied by enzyme kinetics. Compound acted as a free radical scavenger and biometal chelator, crossed the blood-brain barrier, was not cytotoxic, and showed neuroprotective properties in a 6-hydroxydopamine cell model of Parkinson's disease. In addition, studies showed the anti-amnesic effect of in the scopolamine-induced mouse model of AD without adverse effects on motoric function and coordination. Importantly, chronic treatment of double transgenic APPswe-PS1E9 mice with reduced amyloid plaque load in the hippocampus and cortex of female mice, underscoring the disease-modifying effect of QN .

PubMed: 37250172
DOI: 10.1016/j.apsb.2023.01.013

Experimental method

X-RAY DIFFRACTION (2 Å)